Blog
RSS FeedPosted by Michael Wonder on 07 Nov 2023
Germany, Belgium and France among those hit hardest as Commission’s Pharma-legislation proposals risk Europe losing a third of its share of global R&D by 2040
6 November 2023 - The European Federation of Pharmaceutical Industries and Associations (EFPIA) is publishing new research which assesses the ...
Posted by Michael Wonder on 19 Jan 2023
The battle over European drug pricing
19 January 2023 - UK and EU must balance health cost control with plans to grow life sciences. ...
Posted by Michael Wonder on 29 Sep 2022
Europe's generic drugmakers say they may cut output due to energy bills
28 September 2022 - Europe's drugmakers have warned they may stop making some cheap generic medicines because of surging electricity ...
Posted by Michael Wonder on 15 Mar 2022
Drug industry says EMA’s PRIME scheme useful but could be improved
14 March 2022 - Eligibility criteria for admission to the EMA's priority medicines (PRIME) scheme are too strict to facilitate ...
Posted by Michael Wonder on 30 Jan 2022
Medicines regulator pilot probes pharma delays in market launches
25 January 2022 - The European Medicines Agency wants to get a better understanding of drug companies’ commercial intentions and why. ...
Posted by Michael Wonder on 28 Jun 2021
Success rate for marketing authorisation applications from SMEs doubles between 2016 and 2020
28 June 2021 - EMA has published today a report highlighting the Agency’s support for micro, small and medium sized ...
Posted by Michael Wonder on 16 Mar 2021
EU regulators team up with U.S. and UK on pharmaceutical mergers
16 March 2021 - EU antitrust enforcers have teamed up with their U.S. and British counterparts to share expertise on ...
Posted by Michael Wonder on 27 May 2020
Prospective dialogue between developers and regulators makes for better evidence generation
27 May 2020 - EMA, in collaboration with other parties, has recently published two scientific articles outlining the importance of ...
Posted by Michael Wonder on 19 May 2020
Top pharma official rejects idea of free COVID-19 vaccine for all
18 May 2020 - A leading representative of the pharmaceutical industry has downplayed the idea of a vaccine against the ...
Posted by Michael Wonder on 15 Apr 2020
Sanofi and GSK to join forces in unprecedented vaccine collaboration to fight COVID-19
14 April 2020 - Candidate vaccine expected to enter clinical trials in the second half of 2020 and, if successful, to ...
Posted by Michael Wonder on 28 Feb 2019
“Repurposing” off-patent drugs offers big hopes of new treatments
28 February 2019 - Towards the end of 2014 a 66-year-old British man named Alistair had a seizure. A scan ...
Posted by Michael Wonder on 16 Jan 2019
Pharmaceutical industry responds to Brexit vote outcome
15 January 2019 - The Association of the British Pharmaceutical Industry has responded to the outcome of the meaningful vote on ...
Posted by Michael Wonder on 03 Dec 2018
Recognition where it’s due: the Access to Medicines Index and the pharma industry
3 December 2018 - Former CEO of Medicines Australia Brendan Shaw says Bill Gates is correct when he says pharmaceutical ...
Posted by Michael Wonder on 14 Jun 2018
Building synergy between regulatory and HTA agencies beyond processes and procedures—can we effectively align the evidentiary requirements? A survey of stakeholder perceptions
13 June 2018 - The pathway for bringing a new medicine to the market is dependent on two sequential processes: achieving ...
Posted by Michael Wonder on 04 Jun 2018
Two more EU Member States benefit from EU-US mutual recognition agreement for inspections
1 June 2018 - Agreement now operational between 14 EU Member States and FDA. ...